《中国保健协会网》
由 中国保健协会保健品市场工作委员会 主办 快速导航  工作邮箱登录
首  页 | 行业聚焦 | 工作动态 | 市场监督 | 非常观点 | 媒体曝光 | 市场峰会 | 庶正康讯
政策法规 | 注册申报 | 批件搜索 | 市场调研 | 调研报告 | 展会信息 | 信用评价 | English 


互联网 www.chca.net.cn
中国保健行业历年十大事件 | 销售商俱乐部 | 《保健食品注册与备案管理办法》7月1日施行 保健食品原料目录(第一批)征求意见

保健食品科研底子太薄 行业价值苦熬官方认可

庶正康讯微信 2016-4-25  

宏观微点:今天朋友圈里在讨论上海交通大学赵立平教授宁愿辞职也要以个人身份向科技部发起申诉的杯具,颇为感慨。无奈的是,一位手无缚鸡之力的年迈书生,仅靠辞职能撼动僵硬的管理体制吗,我认为毫无可能。

虽然事件的起因是科研经费之争,但其中折射出一个尴尬的困境:中国保健品的行业价值未得到官方充分的认可,甚至是未被重视。赵教授的辞职可能无法引起高层重视,但行业精英却不能视而不见。

中国保健品行业发展了近三十年仍然挣扎在发展的初级阶段,持续增长的巨大消费需求虽哺育出了一个2000亿规模的新兴产业,但行业状态就像是一座晃晃悠悠的空中楼阁,短缺科学体系、产业政策和商业生态的坚实支撑,小小的风吹草动都可能把它掀翻。

十五年前我曾到上海交大拜访过赵立平教授,他就谈到中国保健品要走科学化、定制化和精准化的方向才能有产业地位。 事实上保健品(膳食补充剂)行业在发达国家已经受到政府高度重视,在管理上各有千秋,开始向科技型产业升级。

今天推荐一篇澳大利亚政府澳大利亚贸易委员会商务领事莫博仁(Brent Moore)先生的演讲,澳大利亚政府对于营养保健食品行业的价值认可值得我国的管理者学习和借鉴。

——王大宏

推荐阅读:

4月18日,由庶正康讯举办的2016’中国营养保健食品(春季)峰会成功召开,保健品和跨境购方面最具话语权的政、企、协、研专家交流了“新准入政策下的保健品进口和跨境购”经验心得。澳大利亚政府澳大利亚贸易委员会商务领事莫博仁(Brent Moore)现场进行了分享。


——莫博仁(Brent Moore)

澳大利亚政府澳大利亚贸易委员会 商务领事

China and Australia's trade and investment relationship has grown rapidly over several decades on the back ofremarkable economic complementaritywithiron ore, coal, natural gas, as well as agricultural commodities forming the bulk of Australia’s exports to China.

But China’s economy is changing, with a shift underway from investment and export led growth, to one driven by services and consumption, all against the backdrop of unprecedented urbanisation.  

As a consequence of this we are seeing a clear trend towards a greater diversification in China and Australia’s trade and investment economic partnership - into areas such aspremium food and beverage, consumer goods, services such as aged care and financial services, research and innovation, training and education, and of course greater investment in both directions.

Australia is open for business. Australia is one of the easiest places in the world to do business. Overall, Australia ranks 10th in the world for ease of doing business, and fourth when compared with economies with a similar or larger population. Australia ranks particularly well in the ease of getting credit (4th out of 189 economies) and starting a business (7th out of 189 economies).

Australia has one of the world’s strongest and most efficient regulatory environments and is rated among the most business-friendly economies. The country ranks highly in terms of legal rights, ease of setting up a business and the soundness of its banks. Australia also has one of the lowest financial risk factors in the world and the fourth highest-ranked finance and banking regulatory system.

The quality of governance in Australia ranks among the best in the world. Strong governance is key to economic growth and security, providing a drawcard for multinationals expanding their businesses or considering Australia as a base in the Asian region.


I’d now like to discuss the China Australia Free Trade Agreement (ChAFTA).

-Came into effect 20 December 2015

-Two rounds of tariff cuts, one on implementation on 20 December, another on 1 January 2016 – next round of cuts will be on 1 January 2017

ChAFTAopen’s the door wider for Australian businesses in China, and works to secure our place as a globally competitive home for productive Chinese investment.  

ChAFTA has already eliminated tariffs on most Australian pharmaceuticals and will eliminate tariffs on other health and aged care products such as medical equipment and vitamins products by 2019.

Complementary medicines (also known as 'traditional' or 'alternative' medicines) include vitamin, mineral, herbal, aromatherapy and homoeopathic products.

ComplementaryMedicine Australia (CMA) is the national peak body.

Around 50% of the work of the Association is focused upon Regulatory issues.

CMA also predicted that by 2017-18, the industry in Australia were expected to grow to $4.6 billion, and the industry expects an increase to 45,000 employees over the same period.

This is the Sales of Consumer Health by Category issued on July 2014.

It is expected that the sales of vitamin and dietary supplements will overtake the sales of over-the-counter medicines by 2015. (Consumer Health in Australia, EuromonitorInternational)

Therapeutic Goods Administration is the Australian Government agency for any Pharmaceutical, Medical Device, Complementary Medicine, Cosmetic products, etc. Similar to China Food and Drug Administration.


They show that the medicines are accepted by the Therapeutic Goods Administration for supply in Australia and are included in the ARTG. The number is printed on the outer packaging so that it can be seen easily.

AUST R medicines are assessed for safety, quality and effectiveness. They include all prescription only medicines and many over-the-counter products such as those for pain relief, coughs and colds and antiseptic creams.

Prescription only medicines do not display their purpose on the label as the decision for using them lies with a doctor; however, over-the-counter medicines must have a purpose displayed.

AUST L medicines can only contain pre-approved low-risk ingredients. They are used for minor health problems and are reviewed for safety and quality. They include sunscreens over SPF4 and many vitamin, mineral, herbal and homoeopathic products. A purpose must be included on the label.

There were more than 130,000 Chinese students studying in 2015.

In2015, another milestone to Australia was that there were 1 million Chinese people visited Australia for tourism.

It gave Australia an excellent opportunities to present its fine foods, consumer products and life style to the Chinese middle and upper class consumers. These are also the key market to the Australian complementary medicine industry. People visit or study in Australia, sharing with their family members and friends in China about their experiences and take away in Australia.

责编|陈白雪

本文系庶正康讯原创,转载请注明




本站转载文章版权属原作者,如有版权疑问请致电010-83505145-212。加入保健协会请咨询010-83504221
中国保健协会市场工作委员会 © 2005-2018 版权所有 不得转载 E-mail:xiehui@chca.net.cn 传真:(86)10 83505146
地址:北京右内72号 万博商厦902室 电话:(86)10 83505146(调研业务、信息产品) 83502445(准入咨询) 83504221(协会事务) 83501235(公关事务)
工信部备案号:京ICP备13005185号 北京网聚无限提供网络带宽 公安网监备案号:京公网安备110102006241